THE ISRAELI DIAGNOSTIC CENTER FOR MALIGNANT HYPERTHERMIA - 7-YEARS ACCUMULATED EXPERIENCE

Malignant hyperthermia (MH), a rare pharmacogenetic trait, can be leth al when susceptible individuals are exposed to triggering agents durin g general anesthesia. We present our experience with the caffeine-halo thane in vitro contracture test (IVCT) for the diagnosis of malignant hyperthermia susceptibility, Out of 75 patients that were referred for consultation to the MH diagnostic center over a period of 7 years, we performed muscle biopsies and IVCT in 21 patients. A total of 6 patie nts were found to be MH-positive. Appropriate recommendations for futu re anesthetic management, and additionally, for testing the immediate family were made following a positive diagnosis. Improved familiarity with the syndrome of MH and performance of IVCT when family or clinica l history suggest malignant hyperthermia susceptibility, are imperativ e measures to prevent the potential fatality associated with this synd rome.